{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:56:32Z","timestamp":1780498592373,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The HLA-B*57:01 allele is associated with a hypersensitivity reaction to abacavir. Due to the lack of knowledge of HLA-B*57:01 prevalence in Colombia, routine screening is not performed and is not recommended by the national guidelines. We aimed to determine the prevalence of HLA-B*57:01 in HIV population from Colombia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included na\u00efve HIV-infected adults from 13 cities of the country. The presence of HLA-B*57:01 was determined by using SSP-PCR in blood samples. Prevalence rates were stratified by sex, race, and region of origin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      HLA-B*57:01 allele prevalence in Colombian HIV-infected individuals was 2.7%. When stratifying for the race, the prevalence was 4% for whites, 2.6% for other race (mainly mestizo), and 1.9% for Afro-Colombians. The prevalence varied from 0% up to 11.4% depending on the department of origin. The highest prevalence rates were found in Caldas (11.4%), Antioquia (5%), Risaralda (4.8%), and Valle del Cauca (4.3%). When distributed by country zones, the central, with a racial predominance of Caucasians and mestizos, was the highest (6.0%, 0R\u2009=\u20094.1, CI 1.2\u201312.8,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090,016).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The overall prevalence of HLA-B*57:01 in Colombia was lower than the reported rates for other Latin American countries such as Brazil, Costa Rica, and Argentina, but similar in comparison to Chile and Mexico. The diversity in the racial and ethnic heritage shown in our data supports the recommendation to implement routine screening for the HLA-B*57:01 allele before initiation of abacavir-containing antiretroviral therapy in the Colombian HIV management guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-019-4415-3","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T10:03:23Z","timestamp":1568023403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["HLA-B*57:01 allele prevalence in treatment-Na\u00efve HIV-infected patients from Colombia"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0959-8593","authenticated-orcid":false,"given":"Ernesto","family":"Mart\u00ednez Buitrago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mill\u00e1n","family":"O\u00f1ate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Fernando","family":"Garc\u00eda-Goez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz Marina","family":"Sa\u00f1udo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Consuelo","family":"Rubiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"key":"4415_CR1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. (Updated 25 October 2018). https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf . (2018)."},{"key":"4415_CR2","unstructured":"European AIDS Clinical Society. European AIDS Clinical Society Guidelines Version 9.1., Updated October 2018. http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html . (2018)."},{"key":"4415_CR3","unstructured":"Ministry of Health and Social Protection. Evidence-based clinical practice guidelines for HIV infection care of teenagers (13 years old and older) and adults. (2014)."},{"key":"4415_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S Mallal","year":"2002","unstructured":"Mallal S, et al. HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase. Lancet. 2002;359:6.","journal-title":"Lancet"},{"key":"4415_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","volume":"359","author":"S Hetherington","year":"2002","unstructured":"Hetherington S, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121\u20132.","journal-title":"Lancet"},{"key":"4415_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1345\/aph.1K522","volume":"42","author":"CA Hughes","year":"2008","unstructured":"Hughes CA, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008;42:387\u201396.","journal-title":"Ann Pharmacother"},{"key":"4415_CR7","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S0149-2918(02)80057-1","volume":"24","author":"PG Clay","year":"2002","unstructured":"Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002;24:1502\u201314.","journal-title":"Clin Ther"},{"key":"4415_CR8","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","volume":"23","author":"S Hetherington","year":"2001","unstructured":"Hetherington S, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603\u201314.","journal-title":"Clin Ther"},{"key":"4415_CR9","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1345\/aph.1E202","volume":"38","author":"AG Cutrell","year":"2004","unstructured":"Cutrell AG, Hernandez JE, Fleming JW, Edwards MT, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38:2171\u20132.","journal-title":"Ann Pharmacother"},{"key":"4415_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0149-2918(02)85132-3","volume":"24","author":"W Symonds","year":"2002","unstructured":"Symonds W, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther. 2002;24:565\u201373.","journal-title":"Clin Ther"},{"key":"4415_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1468-1293.2003.00166.x","volume":"4","author":"P Easterbrook","year":"2003","unstructured":"Easterbrook P, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir*. HIV Med. 2003;4:321\u20134.","journal-title":"HIV Med"},{"key":"4415_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4236\/ojgen.2014.41008","volume":"04","author":"C de Ara\u00fajo","year":"2014","unstructured":"de Ara\u00fajo C, et al. Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-1 infected individuals in Brazil. Open J Genet. 2014;04:56\u201362.","journal-title":"Open J Genet"},{"key":"4415_CR13","first-page":"59","volume":"2","author":"F Carolino","year":"2017","unstructured":"Carolino F, et al. Prevalence of abacavir-associated hypersensitivity syndrome and HLA-B*57:01 allele in a Portuguese HIV-positive population: Porto Biomed. J. 2017;2:59\u201362.","journal-title":"J."},{"issue":"6","key":"4415_CR14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"Simon Mallal","year":"2008","unstructured":"Mallal S, et al. HLA-B*57:01 Screening for Hypersensitivity to Abacavir. N Engl J Med. 2008;12. https:\/\/doi.org\/10.1056\/NEJMoa0706135 .","journal-title":"New England Journal of Medicine"},{"key":"4415_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1086\/504874","volume":"43","author":"A Rauch","year":"2006","unstructured":"Rauch A, et al. Prospective genetic screening decreases the incidence of Abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43:99\u2013102.","journal-title":"Clin Infect Dis"},{"key":"4415_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0b013e318046ea31","volume":"45","author":"D Zucman","year":"2007","unstructured":"Zucman D, de Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*57:01 avoids Abacavir hypersensitivity reaction in the ethnically mixed French HIV population. JAIDS J. Acquir Immune Defic Syndr. 2007;45:1\u20133.","journal-title":"JAIDS J. Acquir Immune Defic Syndr"},{"key":"4415_CR17","unstructured":"Waters. Prospective HLA-B57:01 screening and ABC hypersensitivity, a single centre experience. (2007)."},{"key":"4415_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jac\/dkm243","volume":"60","author":"H-Y Sun","year":"2007","unstructured":"Sun H-Y, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*57:01 in HIV-infected patients in Taiwan. J Antimicrob Chemother. 2007;60:599\u2013604.","journal-title":"J Antimicrob Chemother"},{"key":"4415_CR19","first-page":"307","volume":"20","author":"C Orkin","year":"2010","unstructured":"Orkin C, et al. An epidemiologic study to determine the prevalence of the HLA-B*57:01 allele among HIV-positive patients in Europe: Pharmacogenet. Genomics. 2010;20:307\u201314.","journal-title":"Genomics"},{"key":"4415_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11427-013-4438-8","volume":"56","author":"Y Guo","year":"2013","unstructured":"Guo Y, et al. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci China Life Sci. 2013;56:119\u201324.","journal-title":"Sci China Life Sci"},{"key":"4415_CR21","doi-asserted-by":"crossref","unstructured":"Small CB, Margolis DA, Shaefer MS, Ross LL. HLA-B*57:01 allele prevalence in HIV-infected north American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. BMC Infect Dis. 2017;17.","DOI":"10.1186\/s12879-017-2331-y"},{"key":"4415_CR22","unstructured":"Baniasadi. Prevalence of HLA-B*57:01 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV- Infected Patients. 5 (2016)."},{"key":"4415_CR23","first-page":"510","volume":"14","author":"H Poggi","year":"2010","unstructured":"Poggi H, et al. HLA-B*57:01 frequency n Chilean HIV-infected patients and in general population. Braz J Infect Dis. 2010;14:510\u20132.","journal-title":"Braz J Infect Dis"},{"key":"4415_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2217\/pgs.11.31","volume":"12","author":"F Sanchez-Giron","year":"2011","unstructured":"Sanchez-Giron F, et al. Association of the genetic marker for abacavir hypersensitivity HLA-B*57:01 with HCP5 rs2395029 in Mexican mestizos. Pharmacogenomics. 2011;12:809\u201314.","journal-title":"Pharmacogenomics"},{"key":"4415_CR25","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.humimm.2014.09.011","volume":"75","author":"E Arrieta-Bola\u00f1os","year":"2014","unstructured":"Arrieta-Bola\u00f1os E, Madrigal JA, Marsh SGE, Shaw BE, Salazar-S\u00e1nchez L. The frequency of HLA-B\u221757:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. Hum Immunol. 2014;75:1092\u20136.","journal-title":"Hum Immunol"},{"key":"4415_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1590\/S1807-59322011000800030","volume":"66","author":"S Crovella","year":"2011","unstructured":"Crovella S, et al. Frequency of HLA B*57:01 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil. Clinics. 2011;66:1485\u20138.","journal-title":"Clinics"},{"key":"4415_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/tan.12575","volume":"86","author":"M Moragas","year":"2015","unstructured":"Moragas M, et al. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients: HLA-B*57:01 in HIV-1 infected patients. Tissue Antigens. 2015;86:28\u201331.","journal-title":"Tissue Antigens"},{"key":"4415_CR28","unstructured":"Cuenta de Alto Costo. \u201cBolet\u00edn Situaci\u00f3n del VIH, Colombia. 2016\u201d. https:\/\/cuentadealtocosto.org\/site\/index.php\/publicaciones#vih . Accessed 1 December 2017."},{"key":"4415_CR29","unstructured":"Hanratty, D. M. & Meditz, S. W. Colombia: A Country Study. Washington: GPO for the Library of Congress. http:\/\/countrystudies.us\/colombia\/37.htm . (1988)."},{"key":"4415_CR30","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1399-0039.2005.00401.x","volume":"65","author":"AM Martin","year":"2005","unstructured":"Martin AM, Nolan D, Mallal S. HLA-B*57:01 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens. 2005;65:571\u20134.","journal-title":"Tissue Antigens"},{"issue":"1","key":"4415_CR31","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1399-0039.2007.00840.x","volume":"70","author":"E Hammond","year":"2007","unstructured":"Hammond E, Mamotte C, Nolan D, Mallal S. HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay. Tissue Antigens. 2007 Jul;70(1):58\u201361.","journal-title":"Tissue Antigens"},{"issue":"7","key":"4415_CR32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/135965350701200708","volume":"12","author":"E Hammond","year":"2007","unstructured":"Hammond E, Almeida CA, Mamotte C, Nolan D, Phillips E, Schollaardt TA, et al. External quality assessment of HLA-B*5701 reporting: an international multicentre survey. Antivir Ther. 2007;12(7):1027\u201332.","journal-title":"Antivir Ther"},{"key":"4415_CR33","doi-asserted-by":"crossref","unstructured":"Phillips, E. J. Genetic screening to prevent Abacavir hypersensitivity reaction: are we there yet? 3 (2006).","DOI":"10.1086\/504878"},{"key":"4415_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF03256308","volume":"13","author":"E Phillips","year":"2009","unstructured":"Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009;13:1\u20139.","journal-title":"Mol Diagn Ther"},{"key":"4415_CR35","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2174\/138945006779025392","volume":"7","author":"G Suarez-Kurtz","year":"2006","unstructured":"Suarez-Kurtz G, Pena J. S. Pharmacogenomics in the Americas: the impact of genetic admixture. Curr. Drug Targets. 2006;7:1649\u201358.","journal-title":"Drug Targets"},{"key":"4415_CR36","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/clpt.2011.355","volume":"91","author":"MA Martin","year":"2012","unstructured":"Martin MA, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and Abacavir dosing. Clin Pharmacol Ther. 2012;91:734\u20138.","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4415-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4415-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4415-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T19:14:48Z","timestamp":1664306088000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4415-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4415"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4415-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.9819\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9819\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9819\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,9]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the Declaration of Helsinki and the national research regulations. The study received approval by the Institutional Review Board of Corporaci\u00f3n Cient\u00edfica Pedi\u00e1trica in Cali, Colombia (reference number CEI-060-2016). All subjects who agreed to participate in the research provided written informed consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual patient data is presented, therefore consent to publish was not requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EMB reports research grants from ViiV Healthcare\/GSK, financial support for REVIVA foundation and VIHCOL Group (Grupo Colombiano de VIH) from GSK, MSD and Stendhal, and personal fees for presentations and advisory board meetings from GSK, MSD and Stendhal and presentations from Janssen Pharmaceuticals. JMO reports grants from ViiV Healthcare\/GlaxoSmithKline, and personal fees from Merck Sharp & Dohme Colombia. JFO reports personal fees from Merck Sharp and Dohme Colombia. JA reports grants from ViiV Healthcare\/GlaxoSmithKline and grants and personal fees from Merck Sharp & Dohme Colombia SAS. WL reports grants from ViiV Healthcare\/GlaxoSmithKline, personal fees from Janssen Cilag SA, and Merck Sharp & Dohme Colombia; LR reports grants from ViiV Healthcare\/GSK and Merck Sharp & Dohme Colombia. LMS declares no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"793"}}